Hyperkalaemia can lead to increased CV mortality risk in HD Patients5,7-9
RISK OF CV MORTALITY BY SERUM K+ LEVELS9
CKD, chronic kidney disease; CV, cardiovascular; HD, haemodialysis; HF, heart failure; K+, potassium, RAASi, renin-angiotensin-aldosterone system inhibitor.
References: 1. Rastergar A, Soleimani M. Postgrad Med J. 2001; 77:759-764. 2. Collins AJ et al. Am J Nephrol. 2017;46:213-221. 3.Thomsen RW et al. Nephrol Dial Transplant. 2018;33(9):1610-1620 4. Epstein M et.al Am J Manag Care. 2015; 21: S212·S220. 5.Genovesi S et al. Nephrol Dial Transplant. 2009;24(8):2529-2536.6. Aldahi M et al.European Heart Journal. 2017;38:2890-2896. 7. LOKELMA TM granted Fast Track Designation in the US to reduce cardiovascular outcomes in patients on chronic haemodialysis with hyperkalaemia. Available at: https://www.astrazeneca.com/media-centre medical-releases/lokema-granted-fast-track-destintion-in-the-us-to-reduce-cardiovascuIar-outcomes-in patients-on chronic-haemodialysis-with-hyperkalaemia.html. Accessed March 2023. 8. Torlen K et. Al Clin J Am Soc Nephrol. 2012;7(8):1272-1284. 9. Bleyer AJ et.al. Kidney Int. 2006;69(12):2268-2273.